Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with relapsed Ewing sarcoma.
Rashmi Chugh, MD
Advertisement
Rashmi Chugh is a medical oncologist specializing in sarcoma at the University of Michigan.
Articles by Rashmi Chugh, MD
Enrolling pediatric patients and identifying biomarkers for response are the priorities for research of ozekibart in Ewing sarcoma.
Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma.
Rashmi Chugh, MD, describes the background for a study of ozekibart in Ewing sarcoma.
Advertisement
Latest Updated Articles
Promising Responses in Ewing Sarcoma TrialApril 28th 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma
2
Phase 3 Trial of Sacituzumab Govitecan Plus Pembrolizumab Stopped Early in First-Line mNSCLC
3
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
4
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
5